Swedish Financial Statements From 2010 to 2024
| B6E Stock | EUR 26.86 0.00 0.00% |
Check Swedish Orphan financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Swedish Orphan's main balance sheet or income statement drivers, such as , as well as many indicators such as . Swedish financial statements analysis is a perfect complement when working with Swedish Orphan Valuation or Volatility modules.
Swedish |
Swedish Orphan Biovitrum Company Current Valuation Analysis
Swedish Orphan's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Swedish Orphan Current Valuation | 6.67 B |
Most of Swedish Orphan's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Swedish Orphan Biovitrum has a Current Valuation of 6.67 B. This is 53.53% lower than that of the Healthcare sector and 10.22% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all Germany stocks is 59.85% higher than that of the company.
Swedish Orphan Biovitrum Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Swedish Orphan's current stock value. Our valuation model uses many indicators to compare Swedish Orphan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Swedish Orphan competition to find correlations between indicators driving Swedish Orphan's intrinsic value. More Info.Swedish Orphan Biovitrum is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers reporting about 0.52 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Swedish Orphan Biovitrum is roughly 1.91 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Swedish Orphan's earnings, one of the primary drivers of an investment's value.About Swedish Orphan Financial Statements
Swedish Orphan stakeholders use historical fundamental indicators, such as Swedish Orphan's revenue or net income, to determine how well the company is positioned to perform in the future. Although Swedish Orphan investors may analyze each financial statement separately, they are all interrelated. For example, changes in Swedish Orphan's assets and liabilities are reflected in the revenues and expenses on Swedish Orphan's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Swedish Orphan Biovitrum. Please read more on our technical analysis and fundamental analysis pages.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on Frankfurt Stock Exchange in Germany.
Currently Active Assets on Macroaxis
Other Information on Investing in Swedish Stock
Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.